Articles On Telix Pharmaceuticals (ASX:TLX)

In afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.4% to 7,146.3 points. Four ASX shares that are falling more than most t...

Telix Pharmaceuticals (TLX) announces successful $175 million institutional placement which it says will assist with funding of multiple clinical programs and products The company says following completion of the placement it will launch a...

The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial...

Melbourne-headquartered nuclear medicine company Telix Pharmaceuticals (ASX: TLX) has completed a $175 million institutional placement to fund final-stage trials of a prostate cancer therapy and the roll-out of its first commercial product...

Healthcare and life sciences expert Scott Power,who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. The Australian Open has kicked o...

Telix Pharmaceuticals (TLX) enters a trading halt while it plans an upcoming capital raise Currently, there is no information about how much the company is aiming to raise or where the funds will be spent Company shares will be paused unt...

Bearish sentiment is still gripping the local markets, but the ASX managed to pull into itself into positive territory in the last 30 minutes of trading. The benchmark would have slumped more today had it been not for the Mining sector, whi...

ASX-listed oncology company Telix Pharmaceuticals shares have gone into a trading halt as the group prepares to pitch investors for fresh funds. 

Key points ASX-listed Brainchip is flying higher again today after announcing another granted patent The company now holds a significant market capitalisation of over $3.5 billion Based on eligibility criteria, Brainchip could soon be in...

Today, the S&P/ASX 200 Index (ASX: XJO) took a ride to the downside with a powerful blow to tech shares. At the end of the session, the benchmark index finished 1.08% lower at 7,393.9 points. Concerns of interest rate hikes caused by...

Today, the S&P/ASX 200 Index (ASX: XJO) disappointed investors with another red showing. At the end of the session, the benchmark index was down 0.71% to 7,710.7 points. Unfortunately, it was another somewhat sombre showing across the...

The price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the majors underperformed the benchmark S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBJD), whereas many small-cap names came thro...

ASX biotech shares were a mixed bag in 2021. Several of the majors came in behind their benchmarks whilst many smaller players outshone the pack. The sector has been the benefactor of long-term tailwinds in diagnostics and demand for nove...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

21 Dec 2021 - Telix Pharmaceuticals' (ASX:TLX) first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer at an institute in …

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is continuing its good run this week amid a company announcement on its study to treat bladder cancer. The biopharmaceutical company has informed investors it has delivered its first dos...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.75% to 7,346.6 points. Four ASX shares that are climbing more than most today are listed bel...

Telix Pharmaceuticals’ (TLX) first patient has been dosed with TLX250-CDx for non-muscle invasive bladder cancer (NMIBC) TLX250-CDx is being developed by Telix for the purpose of determining whether “indeterminate renal masses” are either...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is all over the place in early trade this morning after the company announced a significant update. The biotechnology company’s shares opened higher today, peaking at $8.15, before plung...

The ASX 200 Health Index (XHJ) is trading higher by 0.92% at the time of writing, compared to the broader index which is down by 0.22%. Cannabis-based medtech company, Emyria Limited (ASX:EMD), has signed an agreement with Seattle-based Cyd...

The US Food and Drug Administration approves Telix Pharmaceuticals (TLX) prostate cancer imaging product, Illuccix The approval of the product offers improved imaging to detect metastatic prostate cancer and determine the most appropriate...

ASX biotech shares provided a mixed bag of results in 2021 with many names underperforming their benchmarks while others flourished amid COVID-19 related tailwinds. Whilst many Aussie biotechs came in behind the pack this year, the S&...

The ASX 200 closed Friday’s trading lower by 0.38%, but was still up 1.6% for the week. The local market was relatively quiet today as nervous investors awaited the key US CPI data to be released tonight (US time). Investors could be bracin...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a disappointing note. At the time of writing, the benchmark index is down 0.5% to 7,349.8 points. Four ASX shares that are not letting that stop them...

Shares in Melbourne-based oncology company Telix Pharmaceuticals Ltd (ASX: TLX) are currently down 2% in the red today, trading at $7.35 apiece. Investors aren’t responding enthusiastically to a company announcement early on during Friday’...

Telix Pharmaceuticals’ (TLX) marketing authorisation application (MAA) submission in Europe for the registration of Illuccix has advanced to the final stage of regulatory review Illuccix is a positron emission tomography (PET) agent for th...

Investing in ASX biotech shares was an underwhelming affair in November. As a basket, the sector lagged key benchmarks, and many names saw substantial declines in value over the month. Renewed fears from the Omicron COVID-19 variant saw in...

08 Dec 2021 - Telix Pharmaceuticals (ASX:TLX) has entered into an exclusive commercial distribution agreement with NUCLIBER for its prostate cancer investigational imaging product …

Telix Pharmaceuticals (TLX) enters an exclusive commercial distribution agreement with NUCLIBER S.A Spain for its prostate cancer investigational imaging product, Illuccix Under the agreement, NUCLIBER will be the distributor and local rep...

Telix Pharmaceuticals (ASX:TLX) has announced an exclusive licence agreement for a novel positron emission tomography radiotracer originating from the Université catholique de Louvain in Belgium.

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product Illuccix, a PET imaging agent, targets a prostate specific membrane antigen which appears on more than 90 per cent...

He’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radiopharm Theranostics (ASX:RAD) to his boardroom rota after the nuclear medicine play listed on the ASX on Thursday – albeit limply. The count...

Highlights The rising population and the rise in health issues are increasing the demand for healthcare products and services. People’s lifestyle is one of the reasons for rising health issues in the present times. TLX, RHT, CYC, IPD,...

Highlights Tissue Repair shares tumbled over 40% on its debut on the ASX. The stock price closed 39.5% below the listing price. The wound healing medicine company raised AU$22 million in its IPO. Shares of biopharmaceutical compan...

Highlights The ASX closed 0.7 per cent lower, down 49.7 points to 7420.4. RBA Governor Philip Lowe stated that the latest data and forecasts do not warrant an increase in the cash rate in 2022. Equities in Asian markets rose while the...

Telix Pharmaceuticals (ASX:TLX) has announced that the first Australian patient has been dosed in the international NOBLE Registry.

The TGA has approved Telix Pharmaceuticals' (ASX:TLX) lead prostate cancer imaging product, Illuccix (TLX591-CDx).

Highlights This health care stock delivered robust returns for investors this year. The stock surged 9% on Tuesday after it received the nod for its cancer imaging product. The biopharma company’s shares surged 850% in the past five y...

While you were watching the Melbourne Cup the ASX retreated, the RBA hinted an interest rate hike could be coming sooner than 2024, and a new IPO gained 165%. The ASX 200 closed at 7,324 points – 0.63% down from yesterday. The best sector w...

ASX biotech shares posted a month of solid gains in October, outpacing the wider market as a whole. For instance, the S&P/ASX 300 Pharmaceuticals & Biotechnology Index (ASPBKD) climbed around 6% after a sharp decline to start the...

Highlights The ASX 200 traded 0.5% lower ahead of the RBA policy decision. Seven of 11 sectors traded in the red, while financial sector declined the most. Top losers on the ASX were IAG, Whitehaven Coal and Brickworks. Australian...

Highlights The ASX 200 was up 0.3% this morning to 7,390. IAG has reduced its profit margin guidance from 13.5%-15.5% to 10%-12%. Seven out of the 11 sectors were trading in the green, with the real estate sector gaining the most, an...

Intelicare nabs MercyCare contract for its AI sensor tech Telix scores TGA approval for prostate cancer imaging product MGC receives Israeli approval for COVID treatment dosing study   Intelicare Holdings (ASX:ICR) Intelicare jumped 35.4...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 0.5% to 7,331.5 points. Four ASX shares that are not letting that hold them back a...

Telix Pharmaceuticals (TLX) has received approval from the Australian drug watchdog for its prostate cancer imaging product The Therapeutic Goods Administrations (TGA) has granted Illuccix a broad clinical indication for certain patients w...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is charging higher, up 4.8% in morning trade to $6.96 per share. Below, we take a look at the latest regulatory approval that looks to be spurring investor interest in the ASX biotech sh...

Following Wall Street’s record levels on Friday, the ASX 200 rebounded to rise by 0.6% today. All sectors were in the green, except for Financials which fell by around 0.6%. The sector was dragged down by Westpac (ASX:WBC), which slumped by...

Telix Pharmaceuticals (ASX:TLX) has announced the first set of peer-reviewed results from the IPAX-1 Ph I/II study of TLX101 in combination with external beam radiation therapy in recurrent glioblastoma multiforme.

MoneyTalks is Stockhead’s regular recap of the stocks, sectors and trends that fund managers and analysts are looking at right now and in this edition we’re looking at big biotechs. Today we hear from James McDonald, portfolio manager of Pe...

The ASX 200 Health Index (XHJ) is up by 1.2% at the time of writing, compared to the broader index which is higher by 1%. Truscreen Group (ASX:TRU) was the best health stock performer, up by 38% after reporting key milestones including the...